Mounjaro Becomes India's Top-Selling Drug at INR100 Crore

Eli Lilly’s anti-obesity drug Mounjaro has become India’s highest-selling pharmaceutical by value in October, with sales touching ?100 crore ($11.38 million).

The surge reflects the growing demand for anti-obesity medications in a country battling rising cases of diabetes and weight-related disorders.

Launched in March, Mounjaro quickly gained a lead over Novo Nordisk’s rival drug Wegovy, which entered the Indian market in June. By the end of October, Mounjaro’s total revenue reached ?333 crore, according to research firm Pharmarack.

 The firm noted that the drug’s consumption volume in October was ten times higher than Wegovy’s, underscoring its strong market acceptance.

Also Read: How Pharma Authentication Tech Enhances ROI and Safety

Mounjaro, based on tirzepatide, belongs to a new class of drugs that target metabolic hormones to control blood sugar and aid weight loss. Originally approved for type-II diabetes, it is now being widely used for obesity management. To extend its reach, Eli Lilly and Cipla have partnered to distribute and promote tirzepatide under a new brand, Yurpeak, which will be priced the same as Mounjaro. The collaboration aims to take the product beyond major cities into semi-urban markets.

Meanwhile, Novo Nordisk has secured approval from India’s Central Drugs Standard Control Organisation (CDSCO) to market its diabetes drug Ozempic, a semaglutide-based injectable. “With Ozempic’s launch, the company would complete its semaglutide portfolio in the country, providing a range of treatments,” said Vikrant Shrotriya, Managing Director of Novo Nordisk India.

Priced between ?14,000 and ?17,500 per month, Mounjaro continues to dominate an anti-obesity market estimated at ?752 crore, driven by India’s 100 million people living with both diabetes and obesity.